Metformine Hudrochloride Eg (Eurogenerics) (Metformin Hydrochloride)

Metformin Hydrochloride reduces hepatic glucose production by inhibiting mitochondrial complex I, thereby decreasing gluconeogenesis. It also improves peripheral insulin sensitivity, enhances glucose uptake in muscle and fat tissue, and modestly reduces intestinal glucose absorption, collectively lowering fasting and post‑prandial blood sugar levels.

The appropriate dose of Metformine Hudrochloride Eg is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

The safety of Metformine Hudrochloride Eg in pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks, and the drug should only be used if clearly needed. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and monitoring with their prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformine Hudrochloride Eg belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors in its mechanism of reducing hepatic glucose output and improving insulin sensitivity. It is generally weight‑neutral and has a low risk of hypoglycemia when used alone, making it a first‑line option for many patients.

Store Metformine Hudrochloride Eg at temperatures below 25 °C, in the original packaging, and protect it from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Metformine Hudrochloride Eg is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition characterized by rapid breathing, muscle pain, and abdominal discomfort. Early recognition and prompt medical attention are essential. Other serious concerns include severe hypoglycemia when combined with insulin or sulfonylureas, and rare allergic reactions.

Metformine Hudrochloride Eg is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those who have experienced lactic acidosis while on metformin therapy. It should also be used with caution in individuals with liver disease or significant heart failure.